Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi shares to begin trading under the symbol “TVRD” on April 16, 2025 Post-transaction cash and cash equivalents expected to fund operations into the second half of 2026 Tvardi anticipates reporting topline data from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmon ...